Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.65 USD
+0.47 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Deciphera Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 306 | 324 | 286 | 552 | 580 |
Receivables | 32 | 22 | 21 | 14 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 21 | 21 | 14 | 6 | 0 |
Other Current Assets | 22 | 25 | 19 | 12 | 14 |
Total Current Assets | 381 | 393 | 339 | 584 | 593 |
Net Property & Equipment | 5 | 7 | 9 | 10 | 6 |
Investments & Advances | 55 | 18 | 45 | 12 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 474 | 454 | 429 | 642 | 622 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 19 | 13 | 12 | 20 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 70 | 65 | 81 | 55 | 39 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 100 | 86 | 97 | 70 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 123 | 112 | 125 | 99 | 76 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,778 | 1,575 | 1,359 | 1,298 | 1,034 |
Retained Earnings | -1,428 | -1,233 | -1,054 | -754 | -488 |
Other Equity | 1 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 351 | 342 | 305 | 544 | 546 |
Total Liabilities & Shareholder's Equity | 474 | 454 | 429 | 642 | 622 |
Total Common Equity | 351 | 342 | 305 | 544 | 546 |
Shares Outstanding | 80.10 | 67.60 | 58.40 | 56.90 | 51.00 |
Book Value Per Share | 4.38 | 5.05 | 5.22 | 9.56 | 10.72 |
Fiscal Year End for Deciphera Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 306 | 339 | 329 | 399 |
Receivables | NA | 32 | 28 | 23 | 22 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 21 | 27 | 25 | 26 |
Other Current Assets | NA | 22 | 24 | 28 | 30 |
Total Current Assets | NA | 381 | 418 | 405 | 476 |
Net Property & Equipment | NA | 5 | 6 | 6 | 7 |
Investments & Advances | NA | 55 | 41 | 64 | 31 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 474 | 498 | 510 | 549 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 26 | 21 | 18 | 20 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 70 | 68 | 59 | 61 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 100 | 93 | 81 | 84 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 123 | 116 | 105 | 109 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 1,778 | 1,763 | 1,736 | 1,722 |
Retained Earnings | NA | -1,428 | -1,381 | -1,332 | -1,283 |
Other Equity | NA | 1 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 351 | 382 | 404 | 440 |
Total Liabilities & Shareholder's Equity | NA | 474 | 498 | 510 | 549 |
Total Common Equity | 0 | 351 | 382 | 404 | 440 |
Shares Outstanding | 80.80 | 80.10 | 80.10 | 78.80 | 78.50 |
Book Value Per Share | 0.00 | 4.38 | 4.76 | 5.13 | 5.61 |